Target intelligence / Profile preview

Prostatic acid phosphatase fragment PAPf39 (PAPf39) (PAPf39)

Target
PAPf39
Molecular classification
Peptide, Amyloid fibril
01

Overview

Prostatic acid phosphatase fragment PAPf39 is a 39-amino acid peptide (residues 248–286) derived from the proteolytic cleavage of prostatic acid phosphatase (PAP), an enzyme highly abundant in human semen (Münch et al., 2007, Nature). This fragment is notable for its ability to spontaneously self-assemble into amyloid fibrils, collectively termed Semen-derived Enhancer of Virus Infection (SEVI) (Roan et al., 2009, J. Clin. Invest.). These fibrils carry a high positive charge, which enables them to bridge the electrostatic repulsion between the negatively charged membranes of HIV-1 virions and target host cells, thereby enhancing viral infectivity by several orders of magnitude (Münch et al., 2007, Nature). Consequently, PAPf39 and the resulting SEVI fibrils are considered critical targets for the development of topical microbicides designed to block the sexual transmission of HIV (Hauber et al., 2009, PNAS). Therapeutic strategies involve using small molecules, such as epigallocatechin gallate (EGCG), or molecular tweezers like CLR01 to inhibit the aggregation of PAPf39 or to disrupt the structure and charge of existing fibrils (Lump et al., 2015, eLife). By neutralizing the proviral activity of these fibrils, these agents aim to reduce the efficiency of HIV transmission during sexual contact.

Other names
SEVISemen-derived enhancer of virus infectionPAP(248-286)Prostatic acid phosphatase 248-286
02

Mechanism of action

Inhibition of PAPf39 peptide aggregation into amyloid fibrils and the neutralization of the cationic surface charge of existing SEVI fibrils to prevent HIV-1 virion attachment to host cells (Hauber et al., 2009, PNAS; Lump et al., 2015, eLife).

03

Biological functions

Enhancement of viral infectionAmyloid formationProtein aggregation
04

Disease associations

InfectionHIV infectionViral transmission
05

Safety considerations

Potential for mucosal irritation in the female reproductive tractOff-target binding to other seminal or vaginal proteins
06

Interacting drugs

Epigallocatechin gallate

3 more in the full profile.

07

Biomarkers

PAPf39 fibril concentration in seminal fluid

Beyond the preview

Go deeper on Prostatic acid phosphatase fragment PAPf39 (PAPf39) (PAPf39).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prostatic acid phosphatase fragment PAPf39 (PAPf39) (PAPf39).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call